Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

After hours: March 12 at 7:31:43 PM EDT Loading Chart for GBCI ...

European shares bounced back on Wednesday following four sessions of declines on optimism around positive developments in the Ukraine-Russia conflict, while a cooler-than-expected U.S. inflation ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...